{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/a4c5de36-8260-4222-8e38-ff997dc73436/689dfef0290bdec8f926e3a1?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Spotting undervalued shares, Savills & weight-loss drugs: The Companies and Markets Show ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b44742e856e989985776/1755186951308-622f6b8a-95e7-4e0e-85e0-37caa562a221.jpeg?height=200","description":"<p>We begin with Hugh Moorhead and recent results from<strong> Savills (SVS)</strong>, which were in line with expectations. Hugh and Dan unpack what divisions brought in the highest profits, a breakdown of a handful of global performances, and what the business’s valuation appears to be.</p><p><br></p><p>Next up James Norrington joins to unpack our latest Big Read on sum-of-the-parts valuations. James explains the thinking behind the piece, how it can help find stocks trading at less than their worth, and how to tell if a company is focusing on the right part of a business.</p><p><br></p><p>Lastly, Julian Hofmann covers <strong>Novo Nordisk (DK:NOVO.B)</strong>, which saw shares rise after <strong>Eli</strong> <strong>Lilly’s (US:LLY)</strong> oral weight-loss pill underwhelmed regulators. Competition is still fierce in the sector, but a new Novo CEO could give the company the boost it needs.</p><p> </p><p><strong>Read more on these topics&nbsp;</strong></p><p><a href=\"https://www.investorschronicle.co.uk/content/badbf029-3a59-46e8-8145-39cc847708a3\" rel=\"noopener noreferrer\" target=\"_blank\">How to spot undervalued shares</a></p><p><a href=\"https://www.investorschronicle.co.uk/deep-dive/\" rel=\"noopener noreferrer\" target=\"_blank\">Deep Dives</a></p><p><br></p><p><strong>Timestamps&nbsp;</strong></p><p><strong>1:16 </strong>Savills</p><p><strong>13:41 </strong>Spotting undervalued shares</p><p><strong>26:33 </strong>Weight loss drugs</p>","author_name":"Investors' Chronicle"}